ACADIA Pharmaceuticals Inc
ACAD23.580USD
+0.050+0.21%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.94BMarktkapitalisierung
17.22KGV TTM
mehr Informationen über ACADIA Pharmaceuticals Inc Unternehmen
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Unternehmensinformationen
BörsenkürzelACAD
Name des UnternehmensACADIA Pharmaceuticals Inc
IPO-datumMay 27, 2004
CEOMs. Catherine Owen Adams
Anzahl der mitarbeiter653
WertpapierartOrdinary Share
GeschäftsjahresendeMay 27
Addresse12830 El Camino Real
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92130
Telefon18585582871
Websitehttps://acadia.com/
BörsenkürzelACAD
IPO-datumMay 27, 2004
CEOMs. Catherine Owen Adams
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.94%
Hedge Fund
36.72%
Investment Advisor/Hedge Fund
23.21%
Research Firm
4.68%
Pension Fund
1.03%
Sovereign Wealth Fund
0.88%
Individual Investor
0.58%
Bank and Trust
0.34%
Private Equity
0.28%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
668
175.40M
104.80%
-13.00M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
2023Q1
589
162.49M
100.16%
-17.75M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
42.88M
25.62%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.77M
11.22%
+8.64M
+85.36%
Mar 31, 2025
The Vanguard Group, Inc.
15.18M
9.07%
+1.26M
+9.02%
Mar 31, 2025
RTW Investments L.P.
8.54M
5.1%
-165.38K
-1.90%
Mar 31, 2025
State Street Global Advisors (US)
6.99M
4.18%
+2.47M
+54.68%
Mar 31, 2025
Point72 Asset Management, L.P.
4.65M
2.78%
+2.42M
+108.35%
Mar 31, 2025
Morgan Stanley & Co. LLC
4.26M
2.54%
-1.74M
-29.03%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.95M
1.77%
+77.40K
+2.69%
Mar 31, 2025
Fred Alger Management, LLC
2.77M
1.66%
+54.90K
+2.02%
Mar 31, 2025
Palo Alto Investors LP
2.66M
1.59%
-84.67K
-3.08%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Alger Weatherbie Enduring Growth ETF
4.69%
First Trust NYSE Arca Biotechnology Index Fund
4.65%
iShares Neuroscience and Healthcare ETF
4.3%
Invesco Biotechnology & Genome ETF
2.58%
ALPS Medical Breakthroughs ETF
2.44%
Tema Neuroscience and Mental Health ETF
2.36%
Virtus LifeSci Biotech Products ETF
1.91%
Invesco S&P SmallCap Health Care ETF
1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
1.58%
Mehr Anzeigen
Alger Weatherbie Enduring Growth ETF
Anteil4.69%
First Trust NYSE Arca Biotechnology Index Fund
Anteil4.65%
iShares Neuroscience and Healthcare ETF
Anteil4.3%
Invesco Biotechnology & Genome ETF
Anteil2.58%
ALPS Medical Breakthroughs ETF
Anteil2.44%
Tema Neuroscience and Mental Health ETF
Anteil2.36%
Virtus LifeSci Biotech Products ETF
Anteil1.91%
Invesco S&P SmallCap Health Care ETF
Anteil1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.58%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
